Akihiko Yura
Showa University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Akihiko Yura.
Brain Research | 1998
Jun Uchida; Yuji Kiuchi; Minoru Ohno; Akihiko Yura; Katsuji Oguchi
Ca(2+)-dependent regulation of [3H]noradrenaline ([3H]NA) uptake through the NA transporter was studied using PC12 cells. Preincubation for 10 min in the presence of 0.3-10 mM ca2+ in Krebs-Ringer (KR) buffer induced marked enhancement of the uptake (at 1 mM Ca2+, 6.6 times greater than that observed in the absence of Ca2+), which reflected both an increase in Vmax and a decrease in K(m) of the uptake process. Preincubation with 1 mM Ca2+ also induced a significant increase in the Bmax and Kd of [3H]desipramine binding. The uptake was still enhanced after washing cells with Ca(2+)-free buffer following preincubation with 1 mM Ca2+. 1-[N, O-bis(5-Isoquinolinesulfonyl)-N-methyl-L-tyrosyl]-4-phenylpiperazine (KN-62), 2-[N-(2-hydroxyethyl)-N-(4-methoxybenzenesulfonyl)]amino-N-(4-c hlo rocinnamyl) -N-methylbenzylamine (KN-93) (inhibitors of Ca2+/calmodulin-dependent kinase II), N-(6-aminohexyl)-5-chloro-1-naphthalenesulonamide (W-7) (a calmodulin antagonist), wortmannin (a myosin light chain kinase inhibitor) significantly reduced Ca(2+)-dependent enhancement of the uptake. Mycalolide B (an inhibitor of actin-myosin interaction) also inhibited the enhancement. Although calphostin C (a protein kinase C (PKC) inhibitor) did not affect the enhancement, 12-o-tetradecanoylphorbol 13-acetate (TPA) inhibited the uptake. A synthetic peptide with a sequence (KKVIYKFFS579 IRGSLW) contained in the intracellular COOH-terminal domain of a rat NA transporter was phosphorylated by purified brain Ca2+/calmodulin-dependent protein kinase II. These results suggest that Ca(2+)-dependent enhancement of the [3H]NA uptake in PC12 cells are mediated by activation of calmodulin-dependent protein kinases, probably through stimulation of translocation of the NA transporter to the plasma membrane and/or direct phosphorylation of the transporter itself.
Journal of Neurochemistry | 2002
Tomoyoshi Uchikawa; Yuji Kiuchi; Akihiko Yura; Noriyuki Nakachi; Yukako Yamazaki; Chie Yokomizo; Katsuji Oguchi
Abstract: We studied effects of Ca2+ in the incubation medium on [3H]dopamine ([3H]DA) uptake by rat striatal synaptosomes. Both the duration of the preincubation period with Ca2+ (0–30 min) and Ca2+ concentration (0–10 mM) in Krebs‐Ringer medium affected [3H]DA uptake by the synaptosomes. The increase was maximal at a concentration of 1 mM Ca2+ after a 10‐min preincubation (2.4 times larger than the uptake measured without preincubation), which reflected an increase in Vmax of the [3H]DA uptake process. On the other hand, [3H]DA uptake decreased rapidly after addition of ionomycin in the presence of 1 mM Ca2+. The Ca2+‐dependent enhancement of the uptake was still maintained after washing synaptosomes with Ca2+‐free medium following preincubation with 1 mM Ca2+. Protein kinase C inhibitors did not affect apparently Ca2+‐dependent enhancement of the uptake, whereas 1‐[N,O‐bis(1,5‐isoquinolinesulfonyl)‐N‐methyl‐l‐tyrosyl]‐4‐phenylpiperazine (KN‐62; a Ca2+/calmodulin‐dependent kinase II inhibitor) and wortmannin (a myosin light chain kinase inhibitor) significantly reduced it. Inhibitory effects of KN‐62 and wortmannin appeared to be additive. N‐(6‐Aminohexyl)‐5‐chloro‐1‐naphthalenesulfonamide hydrochloride (W‐7; a calmodulin antagonist) also remarkably inhibited the enhancement. These results suggest that Ca2+‐dependent enhancement of [3H]DA uptake is mediated by activation of calmodulin‐dependent protein kinases.
Brain Research | 1996
Akihiko Yura; Yuji Kiuchi; Tomoyoshi Uchikawa; Jun Uchida; Yukako Yamazaki; Katsuji Oguchi
Effects of Ca2+ on [3H]5-hydroxytryptamine (5-HT) uptake into rat cortical synaptosomes were studied. The uptake was enhanced in the presence of Ca2+ in Krebs-Ringer medium and the uptake at 0.3-5 mM Ca2+ was 2.4-2.7 times greater than that observed in the absence of Ca2+. The maximal increase at the concentration of 1 mM Ca2+ was achieved after 2 min preincubation. Ca(2+)-dependent enhancement of the [3H]5-HT uptake reflected an increase in Vmax of the uptake process. However, Kd and Bmax values for [3H]paroxetine were not significantly changed in the presence of 1 mM Ca2+ compared with Ca(2+)-free condition. On the other hand, uptake was still enhanced after synaptosomes were washed with Ca(2+)-free after preincubation with 1 mM Ca2+. Staurosporine (a protein kinase C inhibitor) and wortmannin (a myosin light chain kinase inhibitor) did not affect Ca(2+)-dependent enhancement of the uptake, whereas 1-[N,O-bis(5-isoquinolinesulfonyl)-N-methyl-L-tyrosyl]-4-phenylpiperazin e (KN-62, an inhibitor of Ca2+ /calmodulin-dependent kinase II) and N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide hydrochloride (W-7, a calmodulin antagonist) significantly reduced it. Moreover, L-type, but not P- or N-type, voltage-dependent Ca(2+)-channel blockers suppressed enhancement of the uptake. These results indicate that Ca(2+)-dependent enhancement of [3H]5-HT uptake is mediated by activation of calmodulin-dependent protein kinases, suggesting a possibility of calmodulin-dependent regulation of in vivo 5-HT uptake.
Japanese Clinical Medicine | 2016
Yuya Nakamura; Masahiro Inagaki; Mayumi Tsuji; Toshihiko Gocho; Kazuaki Handa; Hitomi Hasegawa; Akihiko Yura; Tomoko Kawakami; Isao Ohsawa; Yoshikazu Goto; Hiromichi Gotoh; Yuji Kiuchi
BACKGROUND Because of the potential anti-inflammatory effects, linagliptin, a therapeutic dipeptidyl peptidase-4 inhibitor, is used as an effective drug for diabetic patients for whom inflammation is a prognosis-related factor. We investigated the anti-inflammatory mechanism of linagliptin using seven markers. METHODS We pretreated human umbilical vein endothelial cells (HUVECs), with linagliptin and lipopolysaccharide (LPS). The cytosolic fractions were evaluated for protein kinase A (PKA), protein kinase B (PKB), protein kinase C (PKC), ratio of reactive oxygen species (ROS) and Cu/Zn superoxide dismutase (SOD), activator protein 1 (AP-1), and adenosine 3′,5′-cyclic monophosphate (cAMP). RESULTS Linagliptin increased the PKA and PKC activities and the cAMP levels in LPS-treated cells. However, it inhibited LPS-induced PKB phosphorylation, ratio of ROS and Cu/Zn SOD, and LPS-stimulated AP-1 nuclear translocation. CONCLUSION We reaffirmed the anti-inflammatory and antioxidant effects of linagliptin. These effects might be related to the three protein kinases. Our findings suggest that linagliptin has a wide range of anti-inflammatory effects.
Anticancer Research | 2002
Keiko Imai; Masahiro Inagaki; Yukako Saitoh; Akihiko Yura; Hiroshi Sakagami; Masako Suzuki; Katsuji Oguchi
Inflammation and Regeneration | 2018
Shiho Yamadera; Yuya Nakamura; Masahiro Inagaki; Sachiyo Kenmotsu; Tetsuhito Nohara; Naoki Sato; Tatsunori Oguchi; Mayumi Tsuji; Isao Ohsawa; Hiromichi Gotoh; Yoshikazu Goto; Akihiko Yura; Yuji Kiuchi; Shinichi Iwai
The Showa University Journal of Medical Sciences | 2008
Shinichi Iwai; Yuki Kamiya; Kazuko Tsujiyama; Mai Murayama; Hiromichi Tsuchiya; Yuri Tomita; Tomoko Kawakami; Akihiko Yura; Masako Okazaki; Katsuji Oguchi
Rinsho Yakuri\/japanese Journal of Clinical Pharmacology and Therapeutics | 2005
Akihiko Yura; Keinosuke Nara; Shinichi Twat; Yuko Udaka; Hiroshi Gomibuchi; Shizuma Tsuchiya; Katsutoshi Ogawa; Katsuji Oguchi
Rinsho Yakuri\/japanese Journal of Clinical Pharmacology and Therapeutics | 2003
Akihiko Yura; Shinichi Twat; Keinosuke Nara; Yuko Udaka; Katsuji Oguchp
Rinsho Yakuri\/japanese Journal of Clinical Pharmacology and Therapeutics | 2001
Akihiko Yura; Yuko Udaka; Katsuji Oguchi